PRODUCT INFORMATION



OH.

ÓН

CFTR Inhibitor II

Item No. 15772

CAS Registry No.: 328541-79-3

Formal Name: 2-[(3,5-dibromo-2,4-dihydroxyphenyl)

methylene]hydrazide N-2-naphthalenyl-glycine

Synonyms: GlyH-101, Cystic Fibrosis Transmembrane

Conductance Regulator Inhibitor II

MF: C₁₉H₁₅Br₂N₃O₃

FW: 493.2 **Purity:** ≥95%

UV/Vis.: λ_{max} : 243, 289, 329 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



CFTR inhibitor II is supplied as a crystalline solid. A stock solution may be made by dissolving the CFTR inhibitor II in the solvent of choice, which should be purged with an inert gas. CFTR inhibitor II is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of CFTR inhibitor II in these solvents is approximately 25 and 30 mg/ml, respectively.

CFTR inhibitor II is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CFTR inhibitor II should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CFTR inhibitor II has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

The cystic fibrosis (CF) gene encodes a cAMP-regulated chloride channel, the CF transmembrane conductance regulator (CFTR).1 CFTR inhibitor II, also known as GlyH-101, is a glycine hydrazide that selectively and reversibly blocks the CFTR channel ($K_i = 4.3 \mu M$).^{2.3} This compound binds to a site at the external pore of CFTR, occluding the pore and rapidly preventing chloride transport.^{2,3} Intraluminal CFTR inhibitor II greatly reduces intestinal fluid secretion induced by cholera toxin.3 It is effective in cells in culture and also in nasal and intestinal epithelia in vivo.4-7

References

- 1. Derand, R., Bulteau-Pignoux, L., and Becq, F. J. Biol. Chem. 277(39), 35999-36004 (2002).
- 2. Sonawane, N.D., Hu, J., Muanprasat, C., et al. FASEB J. 20(1), 130-132 (2006).
- 3. Muanprasat, C., Sonawane, N.D., Salinas, D., et al. J. Gen. Physiol. 124(2), 125-137 (2004).
- MacVinish, L.J., Cope, G., Ropenga, A., et al. Br. J. Pharmacol. 150(8), 1055-1065 (2007).
- 5. Garnett, J.P., Hickman, E., Tunkamnerdthai, O., et al. Br. J. Pharmacol. 168(8), 1946-1960 (2013).
- 6. Schiffhauer, E.S., Vij, N., Kovbasnjuk, O., et al. Am. J. Physiol. Lung Cell. Mol. Physiol. 304(5), L324-L331 (2013).
- 7. Zertal-Zidani, S., Busiah, K., Edelman, A., et al. Diabetologia 56(2), 330-339 (2013).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM